FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360620398> ?p ?o ?g. }

• W4360620398 abstract "<h3>Background and Importance</h3> Erenumab and galcanezumab are two monoclonal antibodies (mAbs) administrated subcutaneously indicated for migraine prophylaxis in adults. As these are newly approved drugs, it is important to know their safety profile. <h3>Aim and Objectives</h3> To analyse the adverse effects (AE) of these mAbs in real life in a tertiary hospital. <h3>Material and Methods</h3> Observational, retrospective, 30-month study ( March 2020 – September 2022). The study included all patients diagnosed with chronic migraine (CM) or episodic migraine (EM) and who received treatment with galcanezumab or erenumab respectively. <h3>The following variables were collected</h3> sex, age, type of migraine, duration of treatment and AE. Data were collected through the outpatient module of the Farmatools® software and the electronic health record, Mambrino XXI®. <h3>Results</h3> Ninety-five patients (92% female, 8% male) with a median age of 50 years (18-73) were included. Of these, 72% had CM and 28% had EM. 45% and 55% of patients received erenumab and galcanezumab respectively. 48 patients (44% erenumab, 56% galcanezumab) experienced some type of AE during treatment, considered mild-moderate in severity. Four patients (75% erenumab, 25% galcanezumab) had to discontinue treatment due to poor tolerability despite prophylactic treatment. 17 (41% erenumab, 59% galcanezumab) had injection site reaction or pain, 27 (48% erenumab, 52% galcanezumab) constipation and 4 (25% erenumab, 75% galcanezumab) nausea and vomiting. AEs were more frequent among patients with CM (65%) vs EM (35%). Comparing the data obtained with those described in other clinical trials, it was observed that the proportion of AEs was very different from that reported in the trials. In addition, there were no cases of nasopharyngitis or respiratory tract infection described as common in the trials. No cardiovascular AEs were observed. <h3>Conclusion and Relevance</h3> Based on the results of our study, it was observed that galcanezumab and erenumab AEs were categorised as mild-moderate. The incidence of AEs was higher for the group of patients receiving galcanezumab. In addition, a small number of patients discontinued treatment due to AEs. It is essential to know the safety profile of newly approved drugs in clinical practice so as to compare them with those described in clinical trials and to see possible differences between them that contribute to generate new evidence. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest" @default.
• W4360620398 created "2023-03-24" @default.
• W4360620398 creator A5008423194 @default.
• W4360620398 creator A5025450699 @default.
• W4360620398 creator A5043936574 @default.
• W4360620398 creator A5073858642 @default.
• W4360620398 creator A5076638061 @default.
• W4360620398 creator A5083298102 @default.
• W4360620398 date "2023-03-01" @default.
• W4360620398 modified "2023-10-01" @default.
• W4360620398 title "5PSQ-107 Safety assessment of erenumab and galcanezumab in clinical practice" @default.
• W4360620398 doi "https://doi.org/10.1136/ejhpharm-2023-eahp.308" @default.
• W4360620398 hasPublicationYear "2023" @default.
• W4360620398 type Work @default.
• W4360620398 citedByCount "0" @default.
• W4360620398 crossrefType "proceedings-article" @default.
• W4360620398 hasAuthorship W4360620398A5008423194 @default.
• W4360620398 hasAuthorship W4360620398A5025450699 @default.
• W4360620398 hasAuthorship W4360620398A5043936574 @default.
• W4360620398 hasAuthorship W4360620398A5073858642 @default.
• W4360620398 hasAuthorship W4360620398A5076638061 @default.
• W4360620398 hasAuthorship W4360620398A5083298102 @default.
• W4360620398 hasBestOaLocation W43606203981 @default.
• W4360620398 hasConcept C126322002 @default.
• W4360620398 hasConcept C197934379 @default.
• W4360620398 hasConcept C2778375690 @default.
• W4360620398 hasConcept C2778541695 @default.
• W4360620398 hasConcept C2780580376 @default.
• W4360620398 hasConcept C2910587157 @default.
• W4360620398 hasConcept C71924100 @default.
• W4360620398 hasConcept C98274493 @default.
• W4360620398 hasConceptScore W4360620398C126322002 @default.
• W4360620398 hasConceptScore W4360620398C197934379 @default.
• W4360620398 hasConceptScore W4360620398C2778375690 @default.
• W4360620398 hasConceptScore W4360620398C2778541695 @default.
• W4360620398 hasConceptScore W4360620398C2780580376 @default.
• W4360620398 hasConceptScore W4360620398C2910587157 @default.
• W4360620398 hasConceptScore W4360620398C71924100 @default.
• W4360620398 hasConceptScore W4360620398C98274493 @default.
• W4360620398 hasLocation W43606203981 @default.
• W4360620398 hasOpenAccess W4360620398 @default.
• W4360620398 hasPrimaryLocation W43606203981 @default.
• W4360620398 hasRelatedWork W1981588447 @default.
• W4360620398 hasRelatedWork W1982089628 @default.
• W4360620398 hasRelatedWork W2006790890 @default.
• W4360620398 hasRelatedWork W2022556905 @default.
• W4360620398 hasRelatedWork W2900121305 @default.
• W4360620398 hasRelatedWork W3179350797 @default.
• W4360620398 hasRelatedWork W3206572053 @default.
• W4360620398 hasRelatedWork W4200628345 @default.
• W4360620398 hasRelatedWork W4251165208 @default.
• W4360620398 hasRelatedWork W4299400104 @default.
• W4360620398 isParatext "false" @default.
• W4360620398 isRetracted "false" @default.
• W4360620398 workType "article" @default.